Skip to main content

MYRIAD GENETICS INC

For the period ended Dec 31, 2024. Filed Feb 28, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 28, 2025

MYGN$5.67-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Cash Flows for the Years Ended

Consolidated Statements of Cash Flows

Years Ended December 31,
202420232022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss$(127.3)$(263.3)$(112.0)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization61.261.952.7
Non-cash lease expense9.511.311.7
Stock-based compensation expense49.840.738.1
Deferred income taxes(2.8)(4.0)(30.8)
Unrecognized tax benefits2.53.4(1.1)
Impairment of goodwill and long-lived assets56.6—16.9
(Gain) loss on termination of lease(3.1)7.7—
Gain on acquisition(2.2)——
Other non-cash adjustments1.54.41.7
Changes in assets and liabilities:
Prepaid expenses and other current assets(3.7)0.21.6
Trade accounts receivable(8.7)(12.5)(10.3)
Inventory(6.2)(1.8)(2.9)
Prepaid taxes0.50.70.7
Other assets—0.6(0.9)
Tenant improvement allowance received—16.318.0
Accounts payable4.7(3.7)(3.5)
Accrued liabilities(41.0)27.2(86.2)
Net cash used in operating activities(8.7)(110.9)(106.3)
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures(19.0)(63.2)(45.3)
Capitalization of internal-use software costs(10.7)(10.1)—
Proceeds from the sale of business, net cash sold8.8——
Acquisitions, net of cash acquired——(57.2)
Purchases of marketable investment securities——(103.2)
Proceeds from maturities and sales of marketable investment securities9.0105.2128.2
Net cash provided by (used in) investing activities(11.9)31.9(77.5)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from common stock issued under stock-based compensation plans5.96.06.3
Payment of contingent consideration recognized at acquisition——(3.0)
Payment of tax withheld for common stock issued under stock-based compensation plans(13.4)(8.8)(10.6)
Proceeds from underwritten public offering, net of costs and discounts—117.6—
Proceeds from revolving credit facility120.080.0—
Repayment of revolving credit facility(119.5)(40.0)—
Fees associated with issuance and refinancing of revolving credit facility—(1.7)(0.7)
Payment on finance leases(0.4)(0.2)—
Net cash provided by (used in) financing activities(7.4)152.9(8.0)
Effect of foreign exchange rates on cash, cash equivalents, and restricted cash(1.0)0.6(0.6)
Net increase (decrease) in cash, cash equivalents, and restricted cash(29.0)74.5(192.4)
Cash, cash equivalents, and restricted cash at beginning of the period140.966.4258.8
Cash, cash equivalents, and restricted cash at end of the period$111.9$140.9$66.4

See accompanying notes to the consolidated financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.